DDX5 and prostate cancer: Moreover, it has been reported that the mTORC1 inhibitor rapamycin enhances docetaxel efficacy against the PC-3 xenograft model, a castration-resistant prostate cancer model, by downregulating survivin.47 In the present study, resveratrol inhibited the mTORC1 pathway by targeting DDX5, and we raise the possibility that resveratrol may augment docetaxel efficacy against castration-resistant prostate cancer.